# Nektar Therapeutics (NKTR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/NKTR
## Company Profile
- Ticker: NKTR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Immunology
## Stock Data
- Close: 73.09 USD
- Market cap: 1978510033.92 USD
- Last updated: 2026-08-05
## Business Overview
### Immune-Regulatory Therapeutics
Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases.
### Rezpegaldesleukin
Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T cells without broadly stimulating conventional effector T cells.
### Atopic-Dermatitis Development
The Phase 3 ZENITH-AD program is designed to test rezpegaldesleukin in moderate-to-severe atopic dermatitis after Phase 2b results showed responses during treatment and follow-up.
### Alopecia-Areata Development
The REZOLVE-AA program evaluates rezpegaldesleukin in severe alopecia areata, including whether treatment effects persist during an off-treatment observation period.
### Type 1 Diabetes and Earlier Pipeline
Rezpegaldesleukin is also being studied in a TrialNet-sponsored Phase 2 type 1 diabetes trial. Nektar's earlier portfolio includes TNFR2-directed antibodies such as NKTR-0165.
## Why The Stock Is Moving

As of Aug 5, 2026, NKTR closed up 0.45% at $73.09. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA end-of-Phase 2 meeting for rezpegaldesleukin in alopecia areata in the second quarter of 2026.
- Initiation of the Phase 3 ZENITH-AD program by July 2026.
- REZOLVE-AA 24-week off-treatment data in the fourth quarter of 2026.
- REZOLVE-AD 52-week off-treatment data in the first quarter of 2027.
- Initial data from a TrialNet-sponsored Phase 2 type 1 diabetes study in 2027.

## Recent News
- 2026-07-28 22:00 EST — [Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-to-announce-financial-results-for-the-second-quarter-on-thur-0e8d09be) — Source: Nektar Therapeutics
- 2026-07-24 20:15 EST — [Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2337a088) — Source: Nektar Therapeutics
- 2026-07-21 11:00 EST — [Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-start-of-phase-3-zenith-ad-program-evaluating-nove-f2b52f43) — Source: Nektar Therapeutics
- 2026-05-27 22:15 EST — [Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: Nektar Therapeutics
- 2026-05-07 20:15 EST — [Nektar Therapeutics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2026-financial-results) — Source: Nektar Therapeutics